U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07017036) titled 'Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients' on May 10.
Brief Summary: The study duration for individual patients will be up to 55 weeks for the 4-weekly and 3- weekly schedule of the treatment which includes 3 weeks for screening, 48 weeks for Study Medication administration and 4 weeks for follow-up assessments
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Primary Immunodeficiency Diseases (PID)
Intervention:
DRUG: IVIG-VImmune
V-Immune will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose)...